Clinical trial
Economic Outcomes in Patients With Stage III Ovarian Cancer Receiving Paclitaxel…
NCT00477867 · Gynecologic Oncology Group, Other · Withdrawn
Key facts
| NCT number | NCT00477867 |
|---|---|
| Title | Economic Outcomes in Patients With Stage III Ovarian Cancer Receiving Paclitaxel and Cisplatin on Clinical Trial GOG-172 |
| Official title | Assessing Economic Outcomes in Women With Stage III Ovarian Cancer Treated With Intravenous Paclitaxel and Cisplatin v. Intravenous Paclitaxel, Intraperitoneal Cisplatin and Intraperitoneal Paclitaxel on GOG #172: A Feasibility Study of Assessing Costs and Medical Resource Use |
| Lead sponsor | Gynecologic Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Withdrawn |
| Study type | Interventional |
| Conditions | Ovarian Cancer |
| Intervention type | Procedure |
| Interventions | quality-of-life assessment |
| Enrollment | 0 |
| First posted | May 24, 2007 |
| Last update posted | Jun 10, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: